Evidence map›Paper›PMID 26788153›Full record

ArticleOncology letters2015

Quantitative analysis of cell-free DNA in ovarian cancer.

Xuefeng Shao, Yan He, Min Ji, Xiaofang Chen, Jing Qi, Wei Shi, Tianbo Hao, Shaoqing Ju

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncology letters, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed, 2 pooled it
1.3field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

36 citing papers in PubMed, 2 syntheses or guidelines pooled it, 57 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Review
  5. Review
  6. Review
  7. Article
  8. Review
  9. Review
  10. Review
  11. Review
  12. Article
  13. Review
  14. Review
  15. Review
  16. Circulating tumor DNA in cancer diagnosis, monitoring, and prognosis.Journal of the Egyptian National Cancer Institute · 2022
    Review
  17. Article
  18. Properties and Application of Cell-Free DNA as a Clinical Biomarker.International journal of molecular sciences · 2021
    Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 1 country.

Xuefeng ShaoDepartment of Clinical Laboratory, Maternity and Child Healthcare Hospital of Nantong, Nantong, Jiangsu 226018, P.R. China.
Yan HeDepartment of Gynecology, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, Xinjiang 830000, P.R. China.
Min JiDepartment of Internal Medicine, Maternity and Child Healthcare Hospital of Nantong, Nantong, Jiangsu 226018, P.R. China.
Xiaofang ChenDepartment of Gynecology, Maternity and Child Healthcare Hospital of Nantong, Nantong, Jiangsu 226018, P.R. China.
Jing QiDepartment of Laboratory of Surgery, Affiliated Hospital of Nantong University, Nantong, Jiangsu 226018, P.R. China.
Wei ShiDepartment of Laboratory of Surgery, Affiliated Hospital of Nantong University, Nantong, Jiangsu 226018, P.R. China.
Tianbo HaoDepartment of Laboratory of Surgery, Affiliated Hospital of Nantong University, Nantong, Jiangsu 226018, P.R. China.
Shaoqing JuDepartment of Laboratory of Surgery, Affiliated Hospital of Nantong University, Nantong, Jiangsu 226018, P.R. China.
Affiliated Hospital of Nantong University · CNNantong Maternity and Child Health Hospital · CNNantong University · CNFirst Affiliated Hospital of Xinjiang Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The aim of the present study was to investigate the association between cell-free DNA (cf-DNA) levels and clinicopathological characteristics of patients with ovarian cancer using a branched DNA (bDNA) technique, and to determine the value of quantitative cf-DNA detection in assisting with the diagnosis of ovarian cancer. Serum specimens were collected from 36 patients with ovarian cancer on days 1, 3 and 7 following surgery, and additional serum samples were also collected from 22 benign ovarian tumor cases, and 19 healthy, non-cancerous ovaries. bDNA techniques were used to detect serum cf-DNA concentrations. All data were analyzed using SPSS version 18.0. The cf-DNA levels were significantly increased in the ovarian cancer group compared with those of the benign ovarian tumor group and healthy ovarian group (P<0.01). Furthermore, cf-DNA levels were significantly increased in stage III and IV ovarian cancer compared with those of stages I and II (P<0.01). In addition, cf-DNA levels were significantly increased on the first day post-surgery (P<0.01), and subsequently demonstrated a gradual decrease. In the ovarian cancer group, the area under the receiver operating characteristic curve of cf-DNA and the sensitivity were 0.917 and 88.9%, respectively, which was higher than those of cancer antigen 125 (0.724, 75%) and human epididymis protein 4 (0.743, 80.6%). There was a correlation between the levels of serum cf-DNA and the occurrence and development of ovarian cancer in the patients evaluated. bDNA techniques possessed higher sensitivity and specificity than other methods for the detection of serum cf-DNA in patients exhibiting ovarian cancer, and bDNA techniques are more useful for detecting cf-DNA than other factors. Thus, the present study demonstrated the potential value for the use of bDNA as an adjuvant diagnostic method for ovarian cancer.

Indexed as

branched DNAcell free DNAovarian cancertumor marker

Identifiers

PMID26788153
PMCPMC4665352
OpenAlexW2129064069

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.